Thelansis

  Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., which focuses on oncology, immunology, and critical care therapies, has announced the FDA approval of IMULDOSA (ustekinumab-srlf). IMULDOSA, a biosimilar to STELARA® (ustekinumab), has been approved for the treatment of various chronic inflammatory conditions, including psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The FDA has granted approval for all indications that the reference medicine, STELARA, is approved for. Publish Date: 14-10-2024   Source: Accord BioPharma, Inc. Psoriasis, affecting approximately 2-3% of the global population, is primarily an inflammatory skin condition characterized by abnormal epidermal differentiation and hyperproliferation. The disease's pathophysiology involves the activation and migration of T-cells to the dermis, leading to the release of cytokines, particularly tumor necrosis factor-alpha (TNF-alpha), which induces inflamm...

 Psoriasis, affecting approximately 2-3% of the global population, is primarily an inflammatory skin condition characterized by abnormal epidermal differentiation and hyperproliferation. The disease's pathophysiology involves the activation and migration of T-cells to the dermis, leading to the release of cytokines, particularly tumor necrosis factor-alpha (TNF-alpha), which induces inflammation and accelerated skin cell production. This condition manifests with various symptoms, including dry, thick, raised patches on the skin covered by a silvery-white scale. These patches often provoke itching, especially in specific areas like the scalp, lower legs, and groin. In cases where psoriasis affects the hands and feet, painful fissures and cracks may develop, impairing manual tasks and walking. Severe psoriasis on the body can also lead to painful fissures and bleeding. Psoriasis is the most common autoimmune disease attributed to an inappropriate activation of the cellular immune sys...

  Psoriasis is primarily an inflammatory skin condition characterized by reactive abnormal epidermal differentiation and hyperproliferation that affects 2-3% of the world's population. The pathophysiology of the disease is primarily characterized by the activation and migration of T-cells to the dermis, which results in the release of cytokines (tumor necrosis factor-alpha, TNF-alpha in particular) that cause inflammation and rapid skin cell production. It can cause many signs and symptoms, including dry, thick, and raised patches on the skin covered with a silvery-white coating called scale, and they can tend to itch. Itching can be especially severe in certain areas, such as the scalp, lower legs, and groin. When Psoriasis affects the hands and feet, painful fissures or cracks can form, requiring the use of one's hands and walking. Severe Psoriasis on the body can also create painful fissures and can bleed. It is considered the most prevalent autoimmune disease caused by inap...

  Psoriasis is primarily an inflammatory skin condition characterized by reactive abnormal epidermal differentiation and hyperproliferation that affects 2-3% of the world's population. The pathophysiology of the disease is primarily characterized by the activation and migration of T-cells to the dermis, which results in the release of cytokines (tumor necrosis factor-alpha, TNF-alpha in particular) that cause inflammation and rapid skin cell production. It can cause many signs and symptoms, including dry, thick, and raised patches on the skin covered with a silvery-white coating called scale, and they can tend to itch. Itching can be especially severe in certain areas, such as the scalp, lower legs, and groin. When Psoriasis affects the hands and feet, painful fissures or cracks can form, requiring the use of one's hands and walking. Severe Psoriasis on the body can also create painful fissures and can bleed. It is considered the most prevalent autoimmune disease caused by inap...